Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma

Drew Spencer, Dou Yu, Ramin A. Morshed, Gina Li, Katarzyna C. Pituch, David X. Gao, Nicola Bertolino, Daniele Procissi, Maciej S Lesniak, Irina V Balyasnikova

Research output: Contribution to journalArticle

Abstract

Glioblastoma (GBM) remains the most lethal and untreatable central nervous system malignancy. The challenges to devise novel and effective anti-tumor therapies include difficulty in locating the precise tumor border for complete surgical resection, and rapid regrowth of residual tumor tissue after standard treatment. Repeatable and non-invasive intranasal application of neural stem cells (NSCs) was recently shown to enable clinically relevant delivery of therapy to tumors. Treatment with chemotactic NSCs demonstrated significant survival benefits when coupled with radiation and oncolytic virotherapy in preclinical models of GBM. In order to further augment the clinical applicability of this novel therapeutic platform, we postulate that the FDA-approved compound, methimazole (MT), can be safely utilized to delay the nasal clearance and improve the ability of NSCs to penetrate the olfactory epithelium for robust in vivo brain tumor targeting and therapeutic actions. METHODS: To examine the role of reversible reduction of the olfactory epithelial barrier in non-invasive intranasal delivery, we explored the unique pharmacologic effect of MT at a single dosage regimen. In our proof-of-concept studies, quantitative magnetic resonance imaging (MRI), immunocytochemistry, and survival analysis were performed on glioma-bearing mice treated with a single dose of MT prior to intranasal anti-GBM therapy using an oncolytic virus (OV)-loaded NSCs. RESULTS: Based on histology and in vivo imaging, we found that disrupting the olfactory epithelium with MT effectively delays clearance and allows NSCs to persist in the nasal cavity for at least 24 h. MT pretreatment amplified the migration of NSCs to the tumor. The therapeutic advantage of this enhancement was quantitatively validated by tissue analysis and MRI tracking of NSCs loaded with superparamagnetic iron oxide nanoparticles (SPIOs) in live animals. Moreover, we observed significant survival benefits in GBM-bearing mice treated with intranasal delivery of oncolytic virus-loaded NSCs following MT injection. CONCLUSION: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.

Original languageEnglish (US)
Pages (from-to)2071-2083
Number of pages13
JournalTheranostics
Volume9
Issue number7
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neural Stem Cells
Nasal Mucosa
Glioblastoma
Methimazole
Oncolytic Virotherapy
Olfactory Mucosa
Therapeutics
Neoplasms
Brain Neoplasms
Magnetic Resonance Imaging
Oncolytic Viruses
Nasal Cavity
Residual Neoplasm
Survival Analysis
Nose
Glioma
Nanoparticles
Histology
Central Nervous System
Immunohistochemistry

Keywords

  • barrier
  • clearance
  • glioblastoma
  • intranasal delivery
  • neural stem cells

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Spencer, Drew ; Yu, Dou ; Morshed, Ramin A. ; Li, Gina ; Pituch, Katarzyna C. ; Gao, David X. ; Bertolino, Nicola ; Procissi, Daniele ; Lesniak, Maciej S ; Balyasnikova, Irina V. / Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma. In: Theranostics. 2019 ; Vol. 9, No. 7. pp. 2071-2083.
@article{ea6be42810974e5cac72bbbd7dfcd471,
title = "Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma",
abstract = "Glioblastoma (GBM) remains the most lethal and untreatable central nervous system malignancy. The challenges to devise novel and effective anti-tumor therapies include difficulty in locating the precise tumor border for complete surgical resection, and rapid regrowth of residual tumor tissue after standard treatment. Repeatable and non-invasive intranasal application of neural stem cells (NSCs) was recently shown to enable clinically relevant delivery of therapy to tumors. Treatment with chemotactic NSCs demonstrated significant survival benefits when coupled with radiation and oncolytic virotherapy in preclinical models of GBM. In order to further augment the clinical applicability of this novel therapeutic platform, we postulate that the FDA-approved compound, methimazole (MT), can be safely utilized to delay the nasal clearance and improve the ability of NSCs to penetrate the olfactory epithelium for robust in vivo brain tumor targeting and therapeutic actions. METHODS: To examine the role of reversible reduction of the olfactory epithelial barrier in non-invasive intranasal delivery, we explored the unique pharmacologic effect of MT at a single dosage regimen. In our proof-of-concept studies, quantitative magnetic resonance imaging (MRI), immunocytochemistry, and survival analysis were performed on glioma-bearing mice treated with a single dose of MT prior to intranasal anti-GBM therapy using an oncolytic virus (OV)-loaded NSCs. RESULTS: Based on histology and in vivo imaging, we found that disrupting the olfactory epithelium with MT effectively delays clearance and allows NSCs to persist in the nasal cavity for at least 24 h. MT pretreatment amplified the migration of NSCs to the tumor. The therapeutic advantage of this enhancement was quantitatively validated by tissue analysis and MRI tracking of NSCs loaded with superparamagnetic iron oxide nanoparticles (SPIOs) in live animals. Moreover, we observed significant survival benefits in GBM-bearing mice treated with intranasal delivery of oncolytic virus-loaded NSCs following MT injection. CONCLUSION: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.",
keywords = "barrier, clearance, glioblastoma, intranasal delivery, neural stem cells",
author = "Drew Spencer and Dou Yu and Morshed, {Ramin A.} and Gina Li and Pituch, {Katarzyna C.} and Gao, {David X.} and Nicola Bertolino and Daniele Procissi and Lesniak, {Maciej S} and Balyasnikova, {Irina V}",
year = "2019",
month = "1",
day = "1",
doi = "10.7150/thno.29581",
language = "English (US)",
volume = "9",
pages = "2071--2083",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "7",

}

Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma. / Spencer, Drew; Yu, Dou; Morshed, Ramin A.; Li, Gina; Pituch, Katarzyna C.; Gao, David X.; Bertolino, Nicola; Procissi, Daniele; Lesniak, Maciej S; Balyasnikova, Irina V.

In: Theranostics, Vol. 9, No. 7, 01.01.2019, p. 2071-2083.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma

AU - Spencer, Drew

AU - Yu, Dou

AU - Morshed, Ramin A.

AU - Li, Gina

AU - Pituch, Katarzyna C.

AU - Gao, David X.

AU - Bertolino, Nicola

AU - Procissi, Daniele

AU - Lesniak, Maciej S

AU - Balyasnikova, Irina V

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glioblastoma (GBM) remains the most lethal and untreatable central nervous system malignancy. The challenges to devise novel and effective anti-tumor therapies include difficulty in locating the precise tumor border for complete surgical resection, and rapid regrowth of residual tumor tissue after standard treatment. Repeatable and non-invasive intranasal application of neural stem cells (NSCs) was recently shown to enable clinically relevant delivery of therapy to tumors. Treatment with chemotactic NSCs demonstrated significant survival benefits when coupled with radiation and oncolytic virotherapy in preclinical models of GBM. In order to further augment the clinical applicability of this novel therapeutic platform, we postulate that the FDA-approved compound, methimazole (MT), can be safely utilized to delay the nasal clearance and improve the ability of NSCs to penetrate the olfactory epithelium for robust in vivo brain tumor targeting and therapeutic actions. METHODS: To examine the role of reversible reduction of the olfactory epithelial barrier in non-invasive intranasal delivery, we explored the unique pharmacologic effect of MT at a single dosage regimen. In our proof-of-concept studies, quantitative magnetic resonance imaging (MRI), immunocytochemistry, and survival analysis were performed on glioma-bearing mice treated with a single dose of MT prior to intranasal anti-GBM therapy using an oncolytic virus (OV)-loaded NSCs. RESULTS: Based on histology and in vivo imaging, we found that disrupting the olfactory epithelium with MT effectively delays clearance and allows NSCs to persist in the nasal cavity for at least 24 h. MT pretreatment amplified the migration of NSCs to the tumor. The therapeutic advantage of this enhancement was quantitatively validated by tissue analysis and MRI tracking of NSCs loaded with superparamagnetic iron oxide nanoparticles (SPIOs) in live animals. Moreover, we observed significant survival benefits in GBM-bearing mice treated with intranasal delivery of oncolytic virus-loaded NSCs following MT injection. CONCLUSION: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.

AB - Glioblastoma (GBM) remains the most lethal and untreatable central nervous system malignancy. The challenges to devise novel and effective anti-tumor therapies include difficulty in locating the precise tumor border for complete surgical resection, and rapid regrowth of residual tumor tissue after standard treatment. Repeatable and non-invasive intranasal application of neural stem cells (NSCs) was recently shown to enable clinically relevant delivery of therapy to tumors. Treatment with chemotactic NSCs demonstrated significant survival benefits when coupled with radiation and oncolytic virotherapy in preclinical models of GBM. In order to further augment the clinical applicability of this novel therapeutic platform, we postulate that the FDA-approved compound, methimazole (MT), can be safely utilized to delay the nasal clearance and improve the ability of NSCs to penetrate the olfactory epithelium for robust in vivo brain tumor targeting and therapeutic actions. METHODS: To examine the role of reversible reduction of the olfactory epithelial barrier in non-invasive intranasal delivery, we explored the unique pharmacologic effect of MT at a single dosage regimen. In our proof-of-concept studies, quantitative magnetic resonance imaging (MRI), immunocytochemistry, and survival analysis were performed on glioma-bearing mice treated with a single dose of MT prior to intranasal anti-GBM therapy using an oncolytic virus (OV)-loaded NSCs. RESULTS: Based on histology and in vivo imaging, we found that disrupting the olfactory epithelium with MT effectively delays clearance and allows NSCs to persist in the nasal cavity for at least 24 h. MT pretreatment amplified the migration of NSCs to the tumor. The therapeutic advantage of this enhancement was quantitatively validated by tissue analysis and MRI tracking of NSCs loaded with superparamagnetic iron oxide nanoparticles (SPIOs) in live animals. Moreover, we observed significant survival benefits in GBM-bearing mice treated with intranasal delivery of oncolytic virus-loaded NSCs following MT injection. CONCLUSION: Our work identified a novel pharmacologic strategy to accelerate the clinical application of the non-invasive NSCs-based therapeutic platform to tackle aggressive brain tumors.

KW - barrier

KW - clearance

KW - glioblastoma

KW - intranasal delivery

KW - neural stem cells

UR - http://www.scopus.com/inward/record.url?scp=85065507012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065507012&partnerID=8YFLogxK

U2 - 10.7150/thno.29581

DO - 10.7150/thno.29581

M3 - Article

VL - 9

SP - 2071

EP - 2083

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 7

ER -